<p>在保诚集团决定收购巴蒂 AXA 人寿保险控股权后，ICICI 保诚人寿保险的急剧抛售重新点燃了投资者对该保险公司增长轨迹的担忧，市场专家告诉 Moneycontrol，关于大宗交易的潜在压力加剧了对以银行保险为主导的增长放缓和持续估值下调的担忧。</p>
<p>5 月 18 日抛售的直接触发因素是保诚集团拟收购巴蒂人寿保险 75% 的股份，这将要求这家英国保险公司根据印度保险法规将其在 ICICI 保诚人寿的约 22% 的持股比例削减至 10% 以下。预计近 12% 的股份出售——估计约为 920 亿印度卢比——加剧了对持续抛售压力和进一步估值压缩的担忧，而此时该保险公司已经面临相对较弱的增长，无法与行业同行相比。</p>
<p>尽管大多数券商并未看到任何直接的运营影响，但这一举动加剧了市场上已有的争论：ICICI 保诚人寿向较慢但更高质量增长的转型是否在结构上限制了其估值倍数。</p>
<p>Bernstein 采取了最谨慎的态度，认为保诚可能实际上是在 “放弃” 通过其在 ICICI 保诚人寿的少数股权创造有意义的价值，而是转向在巴蒂人寿的控股地位，以便直接推动战略和分销。该券商指出，该股票 “便宜且可能会变得更便宜”，质疑谁会在不要求折扣的情况下吸收这笔大额股份出售。</p>
<p>Axis Capital 也对市场份额损失、较弱的持续性趋势和高昂的费用比率表示担忧，同时维持 “增持” 评级，目标价为 625 印度卢比。该券商表示，尽管盈利指标健康且保护产品的吸引力增强，但增长仍然温和。</p>
<p>相比之下，摩根士丹利维持 “增持” 评级，目标价为 670 印度卢比，认为保诚交易并未改变 ICICI 保诚人寿的核心运营基本面。野村证券维持 “买入” 评级，目标价为 680 印度卢比，指出在最新抛售之前，该股票已经明显跑输大盘和同行。</p>
<p>影响投资者情绪的一个核心问题是，在 Sandeep Bakhshi 接任 ICICI 银行首席执行官后，该保险公司自 2018 年以来逐渐放弃了激进的以银行保险为主导的增长。在更严格的治理和对误售的严格控制下，ICICI 保诚对 ICICI 银行渠道的依赖大幅减少，银行贡献从历史上的约 70-75% 降至约 26-30% 的年保费等值。</p>
<p>虽然这一转型提高了产品质量，分散了分销渠道并增强了利润率，但分析师表示，这也限制了激进的销量增长，迫使投资者重新评估该公司，更像是一个稳定的盈利复合体，而不是一个高增长的保险品牌。</p>
<p>最近的财报强化了这种看法。管理层未对 2027 财年的激进增长指引做出承诺，而是强调了以保护为主导的增长、利润率扩张和在动荡的宏观背景下的成本效率。尽管年保费等值增长仍然温和，但由于产品组合的改善，新业务利润率大幅提升。</p>
<p>结果是，该股票现在的估值倍数在大型上市保险公司中处于最低水平之一。ICICI 保诚人寿的交易价格约为 2027 财年内嵌价值的 1.3-1.5 倍，低于 HDFC 人寿保险和 SBI 人寿保险等同行。</p>
<p>对于看涨者来说，这一折扣加上强劲的偿付能力、改善的保护组合和稳定的盈利能力为估值提供了潜在的底线。对于看跌者来说，保诚的股份出售压力、较慢的增长特征和低迷的分销势头引发了对近期是否可能实现有意义的重新评级的质疑。</p>

保诚集团

英国保诚

英国保诚集团

<p>ICICI 保诚人寿保险的股票在保诚集团收购巴蒂 AXA 人寿保险控股权后遭遇抛售，市场对增长和潜在估值压缩表示担忧。对 ICICI 保诚近 12% 股份的出售被担心会增加卖压。尽管一些券商维持积极评级，但其他券商对市场份额损失和增长放缓表示谨慎。该保险公司从激进的银行保险增长转变，导致其估值被重新评估，当前的交易倍数低于同行</p>

<p>The sharp selloff in ICICI Prudential Life Insurance following Prudential plc’s decision to acquire a controlling stake in Bharti AXA Life Insurance has reignited investor concerns around the insurer’s growth trajectory, with fears of a large block-deal overhang adding to worries over bancassurance-led growth slowdown and ongoing valuation de-rating, market experts told Moneycontrol.</p>
<div class="lb-trans"><p>在保诚集团决定收购巴蒂 AXA 人寿保险控股权后，ICICI 保诚人寿保险的急剧抛售重新点燃了投资者对该保险公司增长轨迹的担忧，市场专家告诉 Moneycontrol，关于大宗交易的潜在压力加剧了对以银行保险为主导的增长放缓和持续估值下调的担忧。</p>
</div><p>The immediate trigger for the May 18 selloff was Prudential Plc’s proposed acquisition of a 75% stake in Bharti Life Insurance, which would require the UK insurer to cut its roughly 22% holding in ICICI Prudential Life to below 10% under Indian insurance regulations. The prospect of a nearly 12% stake sale — estimated at around Rs 9,200 crore — has heightened concerns over sustained selling pressure and further valuation compression at a time when the insurer is already grappling with relatively weaker growth versus industry peers.</p>
<div class="lb-trans"><p>5 月 18 日抛售的直接触发因素是保诚集团拟收购巴蒂人寿保险 75% 的股份，这将要求这家英国保险公司根据印度保险法规将其在 ICICI 保诚人寿的约 22% 的持股比例削减至 10% 以下。预计近 12% 的股份出售——估计约为 920 亿印度卢比——加剧了对持续抛售压力和进一步估值压缩的担忧，而此时该保险公司已经面临相对较弱的增长，无法与行业同行相比。</p>
</div><p>While most brokerages do not see any immediate operational impact, the move has amplified an existing market debate: whether ICICI Prudential Life’s transition toward slower but higher-quality growth structurally caps its valuation multiples.</p>
<div class="lb-trans"><p>尽管大多数券商并未看到任何直接的运营影响，但这一举动加剧了市场上已有的争论：ICICI 保诚人寿向较慢但更高质量增长的转型是否在结构上限制了其估值倍数。</p>
</div><p>Bernstein struck the most cautious tone, arguing Prudential may effectively be “throwing in the towel” on meaningful value creation through its minority holding in ICICI Prudential Life and instead pivoting toward a controlling position in Bharti Life where it can drive strategy and distribution directly. The brokerage noted that the stock “is cheap and will likely get cheaper,” questioning who would absorb the large stake sale without demanding a discount.</p>
<div class="lb-trans"><p>Bernstein 采取了最谨慎的态度，认为保诚可能实际上是在 “放弃” 通过其在 ICICI 保诚人寿的少数股权创造有意义的价值，而是转向在巴蒂人寿的控股地位，以便直接推动战略和分销。该券商指出，该股票 “便宜且可能会变得更便宜”，质疑谁会在不要求折扣的情况下吸收这笔大额股份出售。</p>
</div><p>Axis Capital also flagged concerns around market-share losses, weaker persistency trends and elevated expense ratios, while maintaining an “Add” rating with a target price of Rs 625. The brokerage said growth remains modest despite healthy profitability metrics and stronger traction in protection products.</p>
<div class="lb-trans"><p>Axis Capital 也对市场份额损失、较弱的持续性趋势和高昂的费用比率表示担忧，同时维持 “增持” 评级，目标价为 625 印度卢比。该券商表示，尽管盈利指标健康且保护产品的吸引力增强，但增长仍然温和。</p>
</div><p>In contrast, Morgan Stanley maintained an “Overweight” rating with a Rs 670 target price, arguing the Prudential transaction does not alter ICICI Prudential Life’s core operating fundamentals. Nomura retained its “Buy” rating with a Rs 680 target price, pointing out that the stock had already materially underperformed both the broader market and peers before the latest selloff.</p>
<div class="lb-trans"><p>相比之下，摩根士丹利维持 “增持” 评级，目标价为 670 印度卢比，认为保诚交易并未改变 ICICI 保诚人寿的核心运营基本面。野村证券维持 “买入” 评级，目标价为 680 印度卢比，指出在最新抛售之前，该股票已经明显跑输大盘和同行。</p>
</div><p>A central issue weighing on investor sentiment is the insurer’s post-2018 shift away from aggressive bancassurance-led growth after Sandeep Bakhshi took over as CEO of ICICI Bank. Under tighter governance and stricter controls on mis-selling, ICICI Prudential’s dependence on the ICICI Bank channel sharply reduced, bringing down banca contribution from roughly 70-75% historically to about 26-30% of annual premium equivalent.</p>
<div class="lb-trans"><p>影响投资者情绪的一个核心问题是，在 Sandeep Bakhshi 接任 ICICI 银行首席执行官后，该保险公司自 2018 年以来逐渐放弃了激进的以银行保险为主导的增长。在更严格的治理和对误售的严格控制下，ICICI 保诚对 ICICI 银行渠道的依赖大幅减少，银行贡献从历史上的约 70-75% 降至约 26-30% 的年保费等值。</p>
</div><p>While the transition improved product quality, diversified distribution and strengthened margins, analysts say it also capped aggressive volume growth, pushing investors to reassess the company more as a steady profitability compounder rather than a high-growth insurance franchise.</p>
<div class="lb-trans"><p>虽然这一转型提高了产品质量，分散了分销渠道并增强了利润率，但分析师表示，这也限制了激进的销量增长，迫使投资者重新评估该公司，更像是一个稳定的盈利复合体，而不是一个高增长的保险品牌。</p>
</div><p>Recent earnings reinforced that perception. Management refrained from giving aggressive growth guidance for FY27 and instead emphasised protection-led growth, margin expansion and cost efficiency amid a volatile macro backdrop. Annual premium equivalent growth remained modest, though value of new business margins improved sharply due to a better product mix.</p>
<div class="lb-trans"><p>最近的财报强化了这种看法。管理层未对 2027 财年的激进增长指引做出承诺，而是强调了以保护为主导的增长、利润率扩张和在动荡的宏观背景下的成本效率。尽管年保费等值增长仍然温和，但由于产品组合的改善，新业务利润率大幅提升。</p>
</div><p>The result is a stock that now trades at one of the lowest valuation multiples among large listed insurers. ICICI Prudential Life trades at around 1.3-1.5 times FY27 embedded value, below peers such as HDFC Life Insurance and SBI Life Insurance.</p>
<div class="lb-trans"><p>结果是，该股票现在的估值倍数在大型上市保险公司中处于最低水平之一。ICICI 保诚人寿的交易价格约为 2027 财年内嵌价值的 1.3-1.5 倍，低于 HDFC 人寿保险和 SBI 人寿保险等同行。</p>
</div><p>For bulls, that discount alongside strong solvency, improving protection mix and resilient profitability offers a potential floor for valuations. For bears, the Prudential stake-sale overhang, slower growth profile and muted distribution momentum raise questions about whether a meaningful rerating is possible in the near term.</p>
<div class="lb-trans"><p>对于看涨者来说，这一折扣加上强劲的偿付能力、改善的保护组合和稳定的盈利能力为估值提供了潜在的底线。对于看跌者来说，保诚的股份出售压力、较慢的增长特征和低迷的分销势头引发了对近期是否可能实现有意义的重新评级的质疑。</p>
</div>

Prudential’s Bharti Life Bet Triggers Fresh Overhang Fears for ICICI Pru Life

Money Control

摩根士丹利

Nomura Holdings, Inc.

野村控股

保诚

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Macquarie Energy Transition ETF

保诚集团对 Bharti Life 的投资引发了对 ICICI Pru Life 的新一轮担忧